Terms of Use

Translational Research & Strategic Services 

Kinexum guides, designs, and manages strategic and operational solutions to the regulatory, manufacturing, nonclinical,  clinical development, and business challenges necessary to take scientific discoveries to proof of concept and through the product life cycle.

Kinexum teams supplement the strengths of large and small organizations to reach high-value milestones effectively and efficiently.  Kinexum specializes in crafting creative but sound and integrated solutions across scientific disciplines, therapeutic areas, product modalities, and business stages. We respond to emergencies and as well as requests for problem prevention and complex long-range planning. 

 


News and Upcoming events

Kinexum next Public Webinar will be on Friday, 07/13/2018, at 11 am EDT to noon:

 "European Medicine Agency - Some Recent & Anticipated Changes"

Presenter: Dr. Bart Van der Schueren, IG Endocrinoligie UZ Leuzen, Belgian Representative on EMA

Please log in  or dial 888-601-3595


Kinexum Public Webinar is on Friday, 06/08/2018, at 11 am ET to noon:

Rob Claar of HekaBio KK will Present:

Fast Track Cell Therapy Opportunities Under Japanese Regulations 

Click here to see slides

Click here to listen to the recording


Special Webcast interview is now available on audio 

and with slides

Dr. Lawrence Steinman: From Big Hammers to Lasers: 

Lessons learned in targeting the immune system to reverse or prevent disease

Interviewed by Dr. Alexander Fleming             


Kinexum Public Webinar from Friday, 04/27/2018, is now available on audio (please start at minute 11):

David Fox and Phil Katz of Hogan Lovells  will present - 

Regulatory Outlook under FDA Commissioner Scott Gottlieb and DHH Secretary Alex Azar 

Click here to see the invitation



Read More


 

Read More


Read More


 

Recent Articles

Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 Charles M. Alexander, MD

Originally, diabetes was a symptomatic condition with either diabetic ketoacidosis (DKA) in type 1 diabetes or marked weight loss, muscle wasting, and inanition in type 2 diabetes.  Prognosis was dismal for both and the main difference was the rapidity of the patient’s demise.

Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 - Full Article

Early on Commercial Planning Investments within the R&D Process: The Business Case - Martin Lafontaine

Commercial investments within the early phase of R&D generally rank very low on a company’s priority list.  To use a sports expression, commercial investments often don’t make the cut, and get relegated to the bench.

Early on Commercial Planning Investments within the R&D Process: The Business Case - Full Article

Marketing Added Value - Arthur Santora MD, Ph.D

Fosamax was the first treatment for osteoporosis in postmenopausal women approved based phase 3 data demonstrating a reduction in the incidence of vertebral fractures. Marketing Added Value - Full Article

Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 Charles M. Alexander, MD

Originally, diabetes was a symptomatic condition with either diabetic ketoacidosis (DKA) in type 1 diabetes or marked weight loss, muscle wasting, and inanition in type 2 diabetes.  Prognosis was dismal for both and the main difference was the rapidity of the patient’s demise.

Beyond Hemoglobin A1C Consensus Conference - July 21, 2017 - Full Article